Navellier & Associates’s Intellia Therapeutics NTLA Stock Holding History

Navellier & Associates’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,532	Closed	-$418K	–	328
2021 Q4	$418K	Sell	3,532 -36	-1%	-$4.51K	0.06%	229
2021 Q3	$479K	Sell	3,568 -138	-4%	-$20.9K	0.07%	201
2021 Q2	$600K	Sell	3,706 -30	-0.8%	-$2.34K	0.09%	180
2021 Q1	$300K	Hold	3,736	–	–	0.05%	235
2020 Q4	$203K	Buy	+3,736	New	+$136K	0.04%	264

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Navellier & Associates's NTLA Position: Q1 2022 in Review

Navellier & Associates sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 3,532 shares — an estimated $418K sold.

Navellier & Associates first reported a position in NTLA in Q4 2020 and held it in 5 quarters. The position peaked at $600K in Q2 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

Navellier & Associates reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
Navellier & Associates sold 3,532 Intellia Therapeutics shares in Q1 2022, an estimated $418K.
Navellier & Associates first reported a position in Intellia Therapeutics in Q4 2020 and held it in 5 quarters.
Navellier & Associates's Intellia Therapeutics position peaked at $600K in Q2 2021.
348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Navellier & Associates's 13F filing for Q1 2022, filed 29 Apr 2022.